RxDoctor Payments Data

Alison Sallings

Family · Lexington, SCNPI 1073744892

Payments from drug & device makers

$6,243in general payments, 2019–2025

Across 338 payments — averaging $18.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$691
  • AbbVie$671
  • Lilly USA, LLC$473
  • Pfizer$377
  • Novo Nordisk$362
  • Otsuka America Pharmaceutical, Inc.$263
  • plus $3K from 42 others

What the payments were for

  • Food & beverage$6,14398%
  • Education$1002%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$6,243 in reported general payments places this provider in the 95th percentile of 3,248 family providers in South Carolina.

See all family providers in South Carolina

Medicare billing

Part B allowed, 2024
$68,820
Medicare patients
162
Services billed
1,559

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide58$76,869
RexultiBrexpiprazole24$38,153
XifaxanRifaximin12$36,696
EliquisApixaban38$29,886
Trelegy ElliptaFluticasone/Umeclidin/Vilanter22$27,899
RybelsusSemaglutide17$27,437
JanuviaSitagliptin Phosphate22$26,592
Soliqua 100-33Insulin Glargine/Lixisenatide17$24,652
MounjaroTirzepatide20$22,932
Breztri AerosphereBudesonide/Glycopyr/Formoterol29$18,388
LinzessLinaclotide11$15,719
JardianceEmpagliflozin20$15,553
MyrbetriqMirabegron14$15,328
Tresiba Flextouch U-100Insulin Degludec11$13,646
Breo ElliptaFluticasone/Vilanterol16$8,020

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$362$104,30675 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan, Trulance$212$43,16524 claims
Otsuka America Pharmaceutical, Inc.Rexulti$263$38,15324 claims
GSKTrelegy Ellipta, Breo Ellipta$259$35,91938 claims
PfizerEliquis$377$29,88638 claims
MerckJanuvia$62$26,59222 claims
Sanofi-aventis U.S. LLCSoliqua 100-33$97$24,65217 claims
Lilly USA, LLCMounjaro$473$22,93220 claims
AstraZenecaBreztri Aerosphere$691$18,38829 claims
AbbVieLinzess$671$15,71911 claims
Boehringer IngelheimJardiance$106$15,55320 claims
Astellas Pharma US IncMyrbetriq$164$15,32814 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,248 family providers in South Carolina.

Other family in Lexington

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →